- Trials with a EudraCT protocol (882)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
882 result(s) found for: Randomized controlled trials.
Displaying page 1 of 45.
EudraCT Number: 2005-002306-39 | Sponsor Protocol Number: 156-03-236 | Start Date*: 2005-07-15 |
Sponsor Name:Otsuka Maryland Research Institute, Inc. | ||
Full Title: Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long Term Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized with Worsening Congestive Heart Failure | ||
Medical condition: Subjects hospitalized with worsening congestive heart failure (CHF). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: LT (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-004374-27 | Sponsor Protocol Number: ProPATIent | Start Date*: 2006-10-12 |
Sponsor Name:Philipps-University | ||
Full Title: Prospective, randomized, doubleblind, placebo-controlled trial on changes in acetylcholine receptor antibody titres in autoimmune myasthenia gravis after influenza vaccination (ProPATIent) | ||
Medical condition: Generalized Myasthenia gravis with positive antibodies against Acetylcholine-receptors (ICD10GM2006 G70.0) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2014-001050-41 | Sponsor Protocol Number: RP1202 | Start Date*: 2015-06-12 | |||||||||||
Sponsor Name:Robarts Clinical Trials | |||||||||||||
Full Title: A Cluster Randomized Controlled Trial of an Enhanced Treatment Algorithm for the Management of Crohn's Disease | |||||||||||||
Medical condition: Crohn's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000894-26 | Sponsor Protocol Number: BN42083 | Start Date*: 2020-10-12 | |||||||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||||||||||||
Full Title: A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH PRIMARY PROGRESSIVE MULTIPL... | |||||||||||||||||||||||
Medical condition: Primary Progressive Multiple Sclerosis (MS) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: PT (Trial now transitioned) GB (GB - no longer in EU/EEA) HU (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) BG (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000395-97 | Sponsor Protocol Number: GS-US-205-0117 | Start Date*: 2015-02-02 |
Sponsor Name:Gilead Sciences, Inc. [...] | ||
Full Title: A Double-Blind, Multicenter, Multinational, Randomized, Placebo-Controlled Trial Evaluating Aztreonam Lysine for Inhalation in Patients with Cystic Fibrosis, Mild Lung Disease, and P. aeruginosa (A... | ||
Medical condition: Cystic Fibrosis with Mild Lung Disease and P. aeruginosa (AIR-CF4) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2020-000893-69 | Sponsor Protocol Number: BN42082 | Start Date*: 2020-10-28 | ||||||||||||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||||||||||||
Full Title: A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY AND PHARMACOKINETICS OF A HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH RELAPSING MULTIPLE SCLEROSIS | ||||||||||||||||||||||||||||
Medical condition: Relapsing Multiple Sclerosis (MS) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: PL (Trial now transitioned) PT (Trial now transitioned) GB (GB - no longer in EU/EEA) HU (Trial now transitioned) NL (Ongoing) DE (Trial now transitioned) FR (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003660-11 | Sponsor Protocol Number: 74817 | Start Date*: Information not available in EudraCT |
Sponsor Name:Accare | ||
Full Title: Do effects of methylphenidate decline after long-term use? A double-blind, placebo-controlled cross-over study of effects of methylphenidate on cognitive functioning and real world behavior in trea... | ||
Medical condition: Attention Deficit Hyperactivity Disorder (ADHD) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-000893-68 | Sponsor Protocol Number: LAED001 | Start Date*: 2012-11-15 |
Sponsor Name:Fundació Clinic per a la Recerca Biomèdica | ||
Full Title: Differences in endothelial function amongst Sitagliptin and Liraglutide Users: A randomized, open-label, parallel-group and active controlled trial | ||
Medical condition: type 2 diabetes patients not well controlled at the maximum tolerated dose of metformin | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004921-41 | Sponsor Protocol Number: P06332 | Start Date*: 2015-02-24 |
Sponsor Name:Corporation Schering-Plough K.K. | ||
Full Title: Multicenter, double-blind, randomized, placebo-controlled study of mometasone furoate nasal spray in pediatric subjects with perennial allergic rhinitis | ||
Medical condition: perennial allergic rhinitis | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2016-002281-31 | Sponsor Protocol Number: Piromelatine-IOP1 | Start Date*: 2016-09-19 |
Sponsor Name:Neurim Pharmaceuticals (1991) Ltd. | ||
Full Title: A randomized, double-blind, placebo-controlled, study of oral treatment of piromelatine in patients with ocular hypertension (OHT) or primary open angle glaucoma (POAG). | ||
Medical condition: ocular hypertension primary open angle glaucoma | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-006474-23 | Sponsor Protocol Number: BTIIMD-01-EC/21/LIQUEN | Start Date*: 2022-03-16 |
Sponsor Name:BTI I MAS D S.L. | ||
Full Title: Randomized, treatment-controlled clinical trial Conventional efficacy of Plasma Rich in Factors of Growth (PRGF®) in the treatment of atrophic vulvar lichen sclerosus | ||
Medical condition: Vulvar Lichen Sclerosus et atrophicus | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-001662-35 | Sponsor Protocol Number: BTIIMD-02-EC/22/GLAUCOMA | Start Date*: 2022-08-18 |
Sponsor Name:BTI I MAS D S.L. | ||
Full Title: Randomized, double-blind, parallel group clinical trial to evaluate the efficacy and safety of PRGF eye drops as a treatment for dry eye disease in patients with glaucoma | ||
Medical condition: Dry eye disease in patients with glaucoma | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002542-16 | Sponsor Protocol Number: INSIGHT013 | Start Date*: 2020-09-30 | |||||||||||
Sponsor Name:Office of Sponsored Projects, Regents of the University of Minnesota | |||||||||||||
Full Title: An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the... | |||||||||||||
Medical condition: COVID-19 (SARS-CoV-2) infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) GR (Completed) DK (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001227-40 | Sponsor Protocol Number: SMR-2271(SER100-001) | Start Date*: 2013-09-23 | |||||||||||
Sponsor Name:Serodus ASA | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, cross-over, multi-center study assessing the safety, tolerability and efficacy of SER100 10 mg s.c. twice daily for 2 days in patients with Isolated ... | |||||||||||||
Medical condition: Isolated Systolic Hypertension | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) FI (Prematurely Ended) HU (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004946-83 | Sponsor Protocol Number: BR.31 | Start Date*: 2015-02-19 | |||||||||||||||||||||
Sponsor Name:Clinipace GLobal Ltd. | |||||||||||||||||||||||
Full Title: A phase III prospective double blind placebo controlled randomized study of adjuvant MEDI4736 in completely resected non-small cell lung cancer | |||||||||||||||||||||||
Medical condition: Completely resected non-small cell lung cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Trial now transitioned) HU (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) PL (Trial now transitioned) BG (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004081-18 | Sponsor Protocol Number: UM104 | Start Date*: 2012-12-06 |
Sponsor Name:Umecrine Mood AB | ||
Full Title: A randomized, double-blind, placebo-controlled parallel-group study on safety, tolerability, pharmacokinetics and pharmacodynamics of UC1010 administered subcutaneously, single-dosing in healthy wo... | ||
Medical condition: Premenstrual Dysphoric Disorder (PMDD) | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-001296-36 | Sponsor Protocol Number: PCTA206/11 | Start Date*: 2012-03-09 |
Sponsor Name:Photocure ASA | ||
Full Title: A double blinded, prospective, randomized, vehicle controlled, multi-center study of photodynamic therapy with Visonac cream in patients with acne vulgaris | ||
Medical condition: acne vulgaris | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2011-000571-13 | Sponsor Protocol Number: VIC-PSO1 | Start Date*: 2011-05-24 | |||||||||||
Sponsor Name:Gentofte Hospital | |||||||||||||
Full Title: The effect of GLP-1 in psoriasis | |||||||||||||
Medical condition: Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004228-70 | Sponsor Protocol Number: IBP-9414-010 | Start Date*: 2015-12-28 |
Sponsor Name:Infant Bacterial Therapeutics AB | ||
Full Title: A randomized, double blind, parallel-group, dose escalation placebo-controlled multicentre study to investigate the safety and tolerability of IBP-9414 administered in preterm infants | ||
Medical condition: Prevention of necrotizing enterocolitis in preterm infants with birth weight less than or equal to 1,500 grams | ||
Disease: | ||
Population Age: Preterm newborn infants, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001916-44 | Sponsor Protocol Number: MiFlaPRO_2019 | Start Date*: 2020-01-28 |
Sponsor Name:Medical University Innsbruck, Department of Visceral, Transplant und Thoracic Surgery | ||
Full Title: A multicenter, randomized, double blind placebo controlled trial of Micronized purified Flavonoid- Fraction (MPFF) in the management of radiation proctitis | ||
Medical condition: Patients with radiation proctitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
